NASDAQ:LBRKA 24 April 2026

May 9, 2026, 10:02 AM EDT. AbbVie's shares fell 4.1% over the past week, trading near $202, yet posting strong returns of 12.8% over one year and nearly 110% over five years. Using a Discounted Cash Flow (DCF) model, Simply Wall St estimates AbbVie's intrinsic value at about $418.78 per share, implying the stock is undervalued by 51.6%. The DCF projects free cash flow growth from $18 billion to $34.3 billion by 2030. However, valuation scores are mixed, with 3 out of 6 points indicating some caution, reflecting investor reassessment amid shifts in healthcare and AI sector opportunities. AbbVie's peers have outperformed it recently, raising questions about its relative appeal. Investors should weigh these factors when considering an entry point for this large-cap pharmaceutical firm.